BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents™ Portal

  BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap
  BioReagents™ Portal

Business Wire

ALAMEDA, Calif. -- November 14, 2012

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have
announced the launch of LifeMap BioReagents™
(, a new portal offering researchers access
to BioTime’s research product lines including PureStem™ human progenitor cell
lines, PureStem™ packages, clinical and research grade human embryonic stem
cell lines (hES), HyStem^® hydrogels, culture media, and cell differentiation

LifeMap Sciences will be the principle marketing and sales arm for BioTime’s
cell-based products and related reagents for the research community in
academia, research hospitals, and biotech and pharma companies. LifeMap
Sciences holds the exclusive, worldwide license to market GeneCards^® 
(, with over 12 million page visits per year from hundreds
of thousands of unique users worldwide, and MalaCards (, and
plans to launch LifeMap Discovery™, its database for biomedical and stem cell
research, later this quarter.

LifeMap BioReagents™ is integrated with the GeneCards^®, MalaCards, and
LifeMap Discovery™ databases,  thereby providing a large number of biomedical
researchers accessing these databases a means of identifying stem cell
reagents that can enhance research and discovery efforts in a variety of
fields, including stem cell research, developmental biology, mechanisms of
various human diseases, drug discovery and therapeutic discovery and

“There has been growing interest in the PureStem and hES cell lines,” stated
Yaron Guan-Golan, Head of Marketing at LifeMap Sciences. “Our ability to
provide stable, characterized, pure, and scalable cell lines to the research
community and to industry is a big step forward—not only in the study of stem
cells, but also in the understanding of cellular and developmental biology and
human disease, and in the discovery of new therapies. Together with our
LifeMap Discovery™ database, researchers will now be able to immediately
obtain access to cutting-edge embryonic stem and progenitor cell lines as part
of a wealth of developmental and stem cell information that they need for

About LifeMap Sciences, Inc.

LifeMap Sciences’ ( core technology and business is based on
its integrated database suite, the discovery platform for biomedical and stem
cell research. This platform includes GeneCards^®, the leading human gene
database; LifeMap Discovery™, the database of embryonic development, stem cell
research, and regenerative medicine; and MalaCards, the human disease
database. LifeMap Sciences also markets PanDaTox, an innovative, recently
developed, searchable database that can aid in the discovery of new
antibiotics and biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTime’s principal
marketing subsidiary for research products, including PureStem™ human
progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media for
non-therapeutic uses, via its LifeMap BioReagents™ portal. LifeMap Sciences
will utilize its databases as part of its online marketing strategy to reach
life sciences researchers at biotech and pharmaceutical companies and at
academic institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMap’s scientists
utilize LifeMap’s proprietary platform, including LifeMap Discovery™, its stem
cell database along with the GeneCards^® and MalaCards integrated database
suite, to aid in the development of BioTime’s proprietary PureStem™ human
progenitor cell lines into products for the treatment of human diseases,
especially degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select the
progenitor cell lines that are most likely to facilitate the development of
cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company
focused on regenerative medicine and blood plasma volume expanders. Its broad
platform of stem cell technologies is enhanced through subsidiaries focused on
specific fields of application. BioTime develops and markets research products
in the fields of stem cells and regenerative medicine, including a wide array
of proprietary PureStem™ cell lines, HyStem^® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly known as
HyStem^®-Rx), a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. BioTime's therapeutic
product development strategy is pursued through subsidiaries that focus on
specific organ systems and related diseases for which there is a high unmet
medical need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the treatment
of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte
Corporation is developing therapeutic applications of stem cells to treat
orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation,
focuses on the diagnostic and therapeutic applications of stem cell technology
in cancer, including the diagnostic product PanC-Dx™ currently being developed
for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent stem cell
technology to reverse the developmental aging of human cells to treat
cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences,
Inc. markets GeneCards^®, the leading human gene database, and is developing
an integrated database suite to complement GeneCards^® that will also include
the LifeMap™ database of embryonic development, stem cell research and
regenerative medicine, and MalaCards, the human disease database. LifeMap will
also market BioTime research products. BioTime's lead product, Hextend^®, is a
blood plasma volume expander manufactured and distributed in the U.S. by
Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive
licensing agreements. Additional information about BioTime can be found on the
web at

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future
growth in research, technology, clinical development, and potential
opportunities for BioTime and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that are
not historical fact (including, but not limited to statements that contain
words such as "will," "believes," "plans," "anticipates," "expects,"
"estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or commercialization of
potential products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital, and
maintenance of intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements
and as such should be evaluated together with the many uncertainties that
affect the business of BioTime and its subsidiaries, particularly those
mentioned in the cautionary statements found in BioTime's Securities and
Exchange Commission filings. BioTime disclaims any intent or obligation to
update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list:


BioTime, Inc.
Peter Garcia, 510-521-3390, ext 367
Chief Financial Officer
Judith Segall, 510-521-3390, ext 301
LifeMap Sciences, Inc.
Kenneth Elsner, 781-826-7719
Press spacebar to pause and continue. Press esc to stop.